Acrivon Therapeutics

Acrivon has moved ACR-2316 into the randomized dose-expansion phase of its phase 1/2 study and selected 120 mg and 160 mg for further evaluation, given orally once daily on a three-days-on, four-days-off schedule. The decision follows a dose-escalation in 35 participants (30–240 mg), in which a partial response and a disease control rate of 86% were observed among seven lung cancer patients who continued treatment. No treatment-related grade 4 events occurred at the selected doses; grade 3 events were mainly transient hematologic toxicities such as neutropenia. The expansion phase will test ACR-2316 across various lung and non-lung tumor types, randomized 1:1 and dosed according to FDA Optimus principles; ACR-2316 is a WEE1/PKMYT1 inhibitor. » Más en de.investing.com

Shareholders of Acrivon Therapeutics approved an increase in the equity incentive plan by 3,000,000 shares to a total of 8,606,723 shares and voted for an automatic annual reserve increase of up to 5% of the fully diluted shares through 2032. The expanded plan permits various equity-based awards for employees, directors and consultants. Michael Tomsicek and Charles Baum were elected as directors, and PricewaterhouseCoopers was confirmed as the independent auditor. Acrivon continues to exhibit cash burn with a market capitalization of $63.77 million, while early study results for ACR-368 (ORR 52%) prompted positive analyst reactions. » Más en de.investing.com

Acrivon will present clinical data on its lead candidate ACR-368 (prexasertib), a selective CHK1/CHK2 inhibitor, on February 27 at the ESGO congress in Copenhagen from a potentially registration‑enabling phase 2 study in endometrial cancer. The presentation will be given by Dr. Panagiotis Konstantinopoulos of the Dana‑Farber Cancer Institute. The FDA has granted ACR-368 Fast Track designation as a monotherapy and designated the accompanying OncoSignature test as a Breakthrough Device. Acrivon also highlights its AP3 platform for generative phosphoproteomics and is advancing other candidates such as ACR-2316 and ACR-6840. » Más en de.investing.com